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TOKOTRIENOL DALAM DOS PEPEJAL 
 
ABSTRAK 
 
Kajian biokeperolehan oral serbuk Tocomax
®
 20% yang mengandungi campuran 
beberapa jenis tokotrienol telah dijalankan dengan menggunakan tikus Sprague-
Dawley. Kajian tersebut menunjukkan bahawa serbuk Tocomax
®
 20% mempunyai 
biokeperolehan yang separas dengan Tocovid
®
 Suprabio (1.0, 1.0 dan 1.2 kali ganda 
untuk alpha, gamma dan delta tokotrienol masing-masing). Di samping itu, ia juga 
mempunyai biokeperolehan yang lebih tinggi daripada suspensi minyak Tocomin
®
 
50% (1.9, 2.4 dan 2.9 kali ganda untuk alpha, gamma dan delta tokotrienol masing-
masing). 
 
Penggunaan serbuk Tocomax
®
 20% sebagai bahan aktif dalam formulasi tablet yang 
mengandungi tokotrienol menunjukkan bahawa tablet yang memuaskan dapat 
dihasilkan dengan menggunakan Neusilin UFL2 dan US2 sebagai diluents, Ac-Di-
Sol sebagai disintegrant dan magnesium sebagai lubricant, dengan berat tablet 
sebanyak 500 mg setiap tablet. Tablet yang dihasilkan adalah sekata dari segi warna 
dan tidak mempunyai kecacatan seperti ‘capping’. Tablet tersebut juga mempunyai 
masa peleraian yang baik, iaitu 8 minit dan mempunyai berat yang seragam (kurang 
daripada 2%) Tablet dengan formulasi yang optimum juga berjaya dipindahkan ke 
skala yang lebih besar.  
 
xxiv 
 
Suatu kaedah kromatografi cecair prestasi tinggi yang digunakan untuk menentukan 
kuantiti campuran tokotrienol dalam tablet disahkan berdasarkan garis panduan ICH. 
Kaedah asai itu dapat memuaskan criteria pengesahan dari segi ‘linearity’, 
kespesifikan, ketepatan dan kejituan. Kandungan tokotrienol dalam tablet yang 
dihasilkan adalah sebanyak 93.9, 92.6 dan 92.2% untuk alpha, gamma dan delta 
tokotrienol masing-masing. Eksperimen yang selanjutnya menunjukkan bahawa 
tablet yang diformulasikan hanya stabil apabila disimpan dalam suhu 4
0
C dan 
bukannya apabila didedahkan kepada suhu 40
0
C dan 70% RH (kelembapan relatif). 
 
Seterusnya, satu kajian biokeperolehan yang melibatkan sukarelawan manusia 
dijalankan dengan menggunakan tablet Tocomax yang telah dirumuskan dan 
dibandingkan dengan suspensi minyak Tocomin
®
. Profil biokeperolehan yang 
didapati menunjukkan bahawa sukarelawan yang diberi tablet Tocomax adalah lebih 
tinggi daripada suspensi minyak Tocomin
®
 (2.0, 1.7 and 1.9 kali ganda untuk alpha, 
gamma dan delta tocotrienol masing-masing. 
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TOCOTRIENOLS IN SOLID DOSAGE FORM 
 
ABSTRACT 
 
The bioavailability study of Tocomax
®
 20% powder containing mixed tocotrienols 
was carried out using Sprague-Dawley rats. The study showed that Tocomax
®
 20% 
powder had comparative oral bioavailability as the Tocovid
®
 Suprabio (1.0, 1.0 and 
1.2 times for alpha, gamma and delta tocotrienols respectively). In addition, it was 
also found to have better oral bioavailability as compared to Tocomin
®
 50% oily 
formulation (1.9, 2.4 and 2.9 times for alpha, gamma and delta tocotrienol 
respectively). 
 
Subsequent usage of Tocomax
®
 20% powder as the active ingredient for the 
formulation of tablets containing tocotrienols showed that a satisfactory tablet could 
be obtained using Neusilin UFL2 and US2 as the diluent, Ac-Di-Sol as the 
disintegrant and magnesium stearate as the lubricant with the ideal tablet weight of 
500 mg per tablet. The tablets were homogeneous in colour and with no physical 
defects like capping. The tablets also have good disintegration times of 
approximately 8 minutes and were uniform in weight (less than 2%). The tablets with 
the optimized formulation were also successfully up-scaled.  
 
A simple high performance liquid chromatography method used to assay the mixed 
tocotrienols in the tablets was validated in accordance with the ICH guidelines. The 
xxvi 
 
method was found to fulfill validation requirements such as linearity, specificity, 
recovery/ accuracy and precision. The assay of the freshly prepared tablet was 93.9, 
92.6 and 92.2% for alpha, gamma and delta tocotrienols respectively. Further 
stability tests showed that the tablets were stable when kept at 4
0
C but not at other 
storage conditions such as 40
0
C and at 70% RH (relative humidity). 
 
Finally, a bioavailability study involving healthy human volunteers was carried out 
using the formulated Tocomax tablets and compared against Tocomin
®
 oily 
formulation. The profiles for volunteers given Tocomax tablets preparation obtained 
was consistently higher than that of the Tocomin oily formulation (2.0, 1.7 and 1.9 
times for alpha, gamma and delta tocotrienol respectively) when administered as the 
tablet compared to the oily formulation. 
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CHAPTER 1: INTRODUCTION 
1.1 ORAL BIOAVAILABILITY OF DRUGS 
Oral bioavailability of drugs is a term which is misconstrued by many as oral drug 
absorption. It should be emphasized that while oral absorption involves the transit of 
drugs from the mucus membrane of the digestive tract into the blood stream, oral 
bioavailability, refers to the rate and amount of medication being moved from the 
digestive tract to the intended site of action in the body (Ashford, 2002a, Chiou, 
2001). 
 
1.2 FACTORS AFFECTING THE BIOAVAILABILITY OF AN ORAL DRUG 
The oral route is the preferred mode of drug administration due to its ease and 
convenience to the patients (Ashford, 2002a). Oral administration also avoids the 
pain and risk of infection associated with parenteral administrations such as 
intravenous and intramuscular injections (Gavhane and Yadav, 2012). However, 
many factors can affect the bioavailability of drugs given orally. Thus, an 
understanding of these factors is crucial in the development of an effective oral 
medication (Muller et al., 2006). These factors can be classified into physiological, 
physicochemical and formulation factors. 
 
1.2.1 PHYSIOLOGICAL FACTORS 
Some of the main physiological factors which may affect the oral bioavailability 
include gastrointestinal pH, the unstirred water layer, gastrointestinal (GI) membrane, 
pre-systemic metabolism and physiological disorders of the GI tract. 
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1.2.1(a) Gastrointestinal pH 
The pH of the gastrointestinal tract changes gradually from being acidic in the 
stomach region to being alkaline in the intestines and colon area (Fallingborg, 1999). 
The pH also differs between a fasting and a fed stomach (Ashford, 2002a). Since 
unionized drugs molecules penetrate the gastrointestinal membrane more effectively 
than ionized ones, a weakly acidic drug tend to have better absorption in the stomach 
with more drug molecules existing as unionized forms while weakly basic drugs tend 
to have better absorption in the intestine (Schanker et al., 1957). The presence of 
food however, increases the pH of the gastrointestinal tract (Arne, 1978) and 
prolongs the gastric emptying (Jackson et al., 2007, Dressman et al., 1990). The 
prolonged gastric emptying time increases the exposure time of the drug molecules 
to the acidic stomach pH, leading to degradation of pH sensitive drugs such as 
penicilins (Mizen et al, 1995, Simberkoff et al., 1970) and erythromycin (Cachet et 
al., 1989). 
 
1.2.1 (b) The unstirred water layer 
The unstirred water layer is the region sandwiched between the lumen and 
gastrointestinal membrane. It comprises mainly mucus and glycocalyx (Ashford, 
2002a) and is approximately 500 μm thick (Atuma et al., 2000). While it offers 
protection towards the gastrointestinal tract (Strugala et al., 2003), the layer has also 
been shown to hinder the diffusion of certain drugs by binding the drugs to the 
mucus and hence prevents them from crossing the gastrointestinal membrane 
(Loftsson and Brewster, 2011; MacAdam, 1993).  
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1.2.1 (c) Gastrointestinal membrane 
The gastrointestinal membrane, similar to a semi-permeable lipoidal sieve (Hogben 
et al., 1959), is a barrier which allows only the passing of small molecules and ions 
(example, water molecules) through a convoluted passage between the epithelial 
cells lining the gastrointestinal membrane. This is known as the paracellular pathway 
(Gumbiner, 1987). The other route, transcellular pathway, involves the movement of 
drug molecules across the epithelial cells. Transcellular pathway can be sub-divided 
into various mechanisms such as passive diffusion and carrier mediated transport 
(Ashford, 2002a). While the passive diffusion route functions by transporting small 
lipophilic molecules from a high concentration region to a low concentration region, 
the transportation of drugs with very hydrophilic molecules are restricted as they do 
not have sufficient lipid solubility to cross the gastrointestinal membrane (Adson et 
al., 1995). On the other hand, extremely hydrophobic drug molecules were unable to 
solubilize in the aqueous layer of the gastrointestinal lumen before penetrating the 
gastrointestinal membrane. Carrier mediated transport, is further branched into two 
types, namely, active transport and facilitated diffusion (transport). Active 
transportation involved the transportation of drug molecules against a concentration 
gradient through the gastrointestinal membrane and it requires energy, generated 
mainly from the hydrolysis of intracellular adenosine triphosphate (Komarova and 
Malik, 2010). In contrast, facilitated diffusion does not transfer drug molecules 
against a concentration gradient, and thus, does not require energy. The substrates are 
transported through facilitated diffusion down a concentration gradient at a rate 
based on the molecular size and polarity of the molecule itself (Ashford, 2002a). 
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1.2.1(d) Pre-systemic metabolism 
Intestinal P-glycoprotein (P-g) and intestinal metabolizing enzyme (CYP3A4) are 
two widely studied physiological factors that can affect the bioavailability of drugs 
(Ashford, 2002a). While P-gp (encoded by the MDR gene) exerts its effect by 
expelling the drug out of the enterocytes (Juliano and Ling, 1976), CYP3A4 (a 
predominant Phase 1 drug metabolizing species found in humans), functions mainly 
by metabolizing the drug before any effective absorption could take place 
(Koudriakova et al., 1998; Shimada et al., 1994). Both are believed to work 
synergistically as the continuous process of expelling the drug into the lumen by the 
P-gp provided extra exposure for the CYP3A4 to metabolize the drug. P-gp also 
removes metabolites from the enterocytes of the gastrointestinal tract and expels 
them back into the lumen, some of which are substrates of CYP3A4 (Hochman et al., 
2000; Meijerman et al., 2008; Watkins, 1997). However, like most enzymes, both P-
gp and CYP3A4 are saturable and can be inhibited (Sandström et al., 2001) or 
induced (Lemahieu and Maes, 2007; Marzolini, 1994). 
    
1.2.1(e) Physiological disorders  
Aging individuals were shown to undergo physiological changes (Newton, 2004), 
potentially altering drug metabolism as well as its pre-systemic elimination process 
(Wilkinson, 1997). Wilkinson (1997) also noted that patients with liver diseases 
(usually the elderly), often display signs of increased drug bioavailability, especially 
drugs which exhibit high first pass metabolism effects. The impaired hepatic function 
reduces the extent of first pass metabolism, thus, increasing the oral bioavailability of 
the drug given. Other studies which discussed altered drug bioavailability due to 
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diseases such as Parkinson and diabetes include those carried out by Seeberger and 
Hauser (2007), Darwiche et al. (2001) and Hermann et al. (1998).  
 
1.2.2 PHYSICOCHEMICAL FACTORS 
Physicochemical factors refer to the properties of the drug molecule and these 
include solubility and permeability, stability, particle size and polymorphism of the 
drug (Hörter and Dressman, 2001). 
 
1.2.2(a) Solubility and permeability 
Drugs are classified into four classes under the Biopharmaceutics Drug Classification 
Scheme (BCS). While Class I drugs are highly soluble and permeable, the remaining 
classes of drugs faced either solubility, permeability or a combination of both 
problems (Martinez et al., 2002). Poor solubility of a drug will not only lead to 
undesirable drug precipitation (Dai, 2010), but will also produce drug solutions in 
nano-molar concentrations in the gastrointestinal tract. With only trace amounts of 
the soluble drug and even lesser amount of drug being able to permeate the intestinal 
barrier, the oral bioavailability of the drug administered is reduced and therefore, 
insufficient to induce a therapeutic effect on the patient (Bergstrom et al., 2004).  
 
1.2.2(b) Stability of the drug 
The stability of a drug is important so that minimal degradation occurs upon 
exposure to the harsh conditions of the gastrointestinal tract. A drug is said to be 
stable in the gastrointestinal tract if less than 5% of the drug is degraded after 
incubation in stimulated gastric fluids and stimulated intestinal fluids for 1 and 3 
hours respectively (Asafu-Adjaye et al., 2007). To increase the stability of a drug, 
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numerous formulation techniques have been employed. An example would be the 
introduction of enteric coated tablets whereby the drug would be released from its 
enteric coat to the site of absorption upon contact with the alkaline pH (Fujii et al., 
2011). Meanwhile, Petereit and Weisbrod (1999) utilized methacrylate copolymers 
as tablet coatings to make the drug more stable. 
 
1.2.2(c) Particle size and polymorphism of the drug 
Drugs with smaller particle size have larger surface volume, thus, enabling the drug 
to have maximum possible solubility before absorption takes place (Jinno et al., 
2006). This concept has been utilized by formulators in efforts to increase the 
bioavailability of poorly water soluble drugs such as danazol (Liversidge and Cundy, 
1995). The particle size of a drug can be reduced by various methods such as 
micronization, nanosuspension, sonocrystallisation and supercritical fluidation 
(Mohanachandran et al., 2010).   
 
Polymorphism leads to the occurrence of the same drug having a series of different 
physicochemical properties (Raw et al., 2004). The difference is mainly due to the 
different crystal packing arrangements in the drug itself, thereby giving rise to 
different properties such as melting points, chemical reactivity, dissolution rates and 
therefore, different bioavailability (Ashford, 2002b and Rustichelli et al., 2000). 
Polymorphic forms such as crystallines are in general chemically more stable than 
their amorphous counterpart but are seldom favored due to difficulties in dissociation 
and dissolution (Choi et al., 2004; Snider et al., 2004). Hence, a meta-stable drug 
form is usually used in formulations (Kawakami, 2012; Singhal and Curatolo, 2004). 
The effects of different polymorphic drugs forms on bioavailability can be seen 
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through studies carried out by Kobayashi et al. (2001). It is also noted that 
polymorphic transformations between the different drug forms can be affected by 
environmental conditions such as humidity and moisture uptake (Cheng and Lin, 
2008). 
 
1.2.3 FORMULATION FACTORS 
Formulation factors include the type of dosage forms and excipients used (Goole et 
al., 2010). The absorption of drugs in solid forms such as tablets is governed by the 
rate of disintegration followed by the rate of dissolution. Thus, drugs in liquid dosage 
forms such as suspensions and emulsions are more readily absorbed (Compton et al., 
2006).  
 
Pharmaceutical excipients constitute the bulk properties of tablets and contribute 
vastly towards the dosage, stability and bioavailability of an active ingredient (Pifferi 
and Restani, 2003; Schulze et al., 2005). Any incompatibility of tabletting excipients 
with the drug may cause undesirable interactions which may be determined through 
various methods such as differential scanning calorimetry or microscopic methods 
(Mura et al., 1998). Tablet lubricants such as magnesium stearate are commonly 
added to facilitate the smooth ejection of tablets from the tabletting machine. 
Excessive addition of magnesium stearate however, repels water and increases the 
disintegration time (Llusa et al., 2009). Another excipient, polyvinylpyrrolidone 
(PVP), is found to interact and form solid bridges with the actives upon storage at 
high moisture conditions, prolonging the disintegration time (Zelko et al., 2000). 
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Under formulation factor, the size and density of the granules are also found to 
influence the bioavailability of the drug as well (Hegedus and Pintye-Hodi, 2007). 
Heavier and denser granules are shown to be retained in the stomach region for a 
longer period of time whereas smaller size granules tend to empty quicker, giving 
rise to a difference in bioavailability though the formulation may consist of the same 
active drug and excipients (Newton, 2010). Other effects of formulation and process 
variables on the release of drugs include the method of manufacturing, for example; 
wet granulation or through direct compression (Kranz and Wagner, 2006). In their 
study, the authors found that formulation of the studied drug through wet granulation 
method produced tablets with faster release rate profiles as the method had produced 
tablets which were porous and were able to take up liquid rapidly. 
 
1.3 TOCOTRIENOLS 
1.3.1 INTRODUCTION 
Tocotrienols are part of Vitamin E family, the other half of which is the highly 
popular tocopherols. Both tocotrienols and tocopherols have 4 isomeric members, 
namely the alpha, beta, gamma and delta (α, β, γ and δ). These isomers are easily 
identified by the number and position of the methyl groups on the chromanol head. 
While the tocopherols contain a chromanol head and a saturated phytyl tail, the 
tocotrienols on the other hand, possess a chromanol head with unsaturated isoprenoid 
side chain at positions 3’, 7’ and 11’ (Figure 1.1).  
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Type of tocotrienol R1 R2 
α tocotrienol CH3 CH3 
β tocotrienol CH3 H 
γ tocotrienol H CH3 
δ tocotrienol H H 
Figure 1.1: Chemical structure of tocotrienols 
 
1.3.2 PHARMACOKINETICS OF TOCOTRIENOLS  
Several analytical methods have been developed to determine the pharmacokinetics 
of tocotrienols. These include the usage of high performance liquid chromatography 
(HPLC) with fluorescence detection (Grebenstein and Frank, 2012; Yap et al., 1999), 
HPLC with ultraviolet detection (Abuasal et al., 2011, Katsanidis and Addis, 1999) 
and LCMS/MS (Liang et al., 2013). Each method of detection has its own 
advantages and disadvantages. The optimal procedure is largely dependant on the 
matrix (plasma or animal tissues) containing the tocotrienols itself. 
 
In general, the bioavailability of tocotrienols is poor and erratic. Nevertheless, 
studies carried out by Yap et al. (2003) showed that although the bioavailability of 
tocotrienols administered orally was low and incomplete, it was still better compared 
to other routes of administration such as intraperitoneal or intramuscular. The 
bioavailability of tocotrienols administered after an intake of oily food was also 
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observed to increase after healthy human volunteers were given a high fat meal just 
before administration of the drug.  
 
1.3.3 POTENTIAL HEALTH BENEFITS 
1.3.3(a) Antioxidant properties 
Oxidative stress occurs whenever there is an imbalance between the production of 
reactive oxygen species and the corresponding protective detoxifying mechanisms in 
the body (Blokhina and Fagerstedt, 2010; Maccarrone et al., 2001). As a result, the 
deoxyribonucleic acid (DNA), bodily proteins and lipids may be damaged (Sies, 
1991). Tocotrienols, which belong to the lipid soluble antioxidant group, demonstrate 
its antioxidative activities by neutralizing peroxyl and alkoxyl radicals produced 
during lipid peroxidation (Burton et al., 1983). Lipid peroxidation is detrimental to 
health because it modifies, inactivates and damages important cellular components 
(Yoshida et al., 2007). Peroxidation of low density lipoprotein (LDL)-lipids also 
initiates the pathogenesis of atherosclerosis. Due to LDL being oxidized, this 
modified particle is recognized by the scavenger cell receptor on macrophages. As a 
consequence, massive amounts of cholesterol are deposited into these cells and thus, 
foam cells are generated. Tocotrienols which are known to produce antioxidative 
effects are able to reduce foam cell formation by inhibiting LDL peroxidation 
(Steinberg et al., 1989).  
 
1.3.3(b) Cholesterol lowering properties and prevention of cardiovascular diseases. 
Tocotrienols as anti-cholesterol agents were first presented by Qureshi et al. (1986), 
whereby tocotrienol-rich fractions (TRF) extracted from barley was found to inhibit 
the biosynthesis of cholesterol when fed to rats and chickens. Tocotrienols inhibit the 
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synthesis of cholesterol by down-regulating HMG-CoA reductase enzyme (Elson and 
Qureshi, 1995; Minhajuddin et al., 2005) and by encouraging the degradation of this 
enzyme (Khor et al., 1995; Parker et al., 1993). Tocotrienols also reduce both 
apolipoprotein B and lipoprotein A, a component of VLDL (very low density 
lipoprotein) as high levels of apolipoprotein B increased the risk of premature 
coronary artery disease (Theriault et al., 1999).   
 
Nevertheless, the property of tocotrienols as potential cholesterol lowering agent 
varies in different human studies. For example, tocotrienols given to human subjects 
did not alter the content of cholesterol in the serum (Tomeo et al. 1995).  The same 
findings were published by Mensink et al. (1999); O’Byrne et al. (2000); Rasool et al. 
(2006, 2008). On the contrary, Ladeia et al. (2008) showed that the amount of serum 
lipid decreased statistically when a palm oil-rich diet was given to healthy young 
individuals.  
 
1.3.3(c) Anti-cancer properties: 
Tocotrienols were found to have anti-proliferative (Behery et al., 2012) and pro-
apoptotic properties (Miyazawa et al., 2009) with the ability to reduce the incidence 
and recurrence of cancer (Schwenke, 2002; Sylvester and Shah, 2005). For example, 
women who consume less than 4 mg/ day of tocotrienols through food intake were at 
risk of developing cancer. This is because the natural female hormone, 17β-estradiol 
(E2), tends to undergo epoxidation under stressed conditions and thus, activating 
many of the common chemical carcinogens. Tocotrienols were found to reduce the 
activation of E2-eposide (Yu et al., 2005). Meanwhile, Srivastava and Gupta (2006) 
demonstrated that supplementation of tocotrienols induced cell cycle arrest and 
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apoptosis selectivity in human prostate cancer cells. Other studies of tocotrienols as 
promising anticancer drugs include research on breast cancer cells (Guthrie et al., 
1997; Pierpaoli et al., 2010).  
 
1.3.3(d) Diabetes and hypertension 
The endothelium refers to the inner layer of blood vessels with the function to 
regulate vascular tone and to ensure the flow of blood in the vessels is not distrupted 
(Calles-Escandon and Cipolla, 2001). An impairment of the function of the 
endothelium (endothelial dysfunction), may result in the loss of physiological 
functions such as the ability to promote vasodilatation, fibrinolysis and anti-
aggregation due to over production of reactive oxygen species and uncontrolled 
oxidative stress (Anderson, 2003). This will eventually lead to complications and 
diseases such as diabetes and hypertension (Balakumar et al., 2009). Experiments 
conducted by Muharis et al. (2010), showed that tocotrienols restored the endothelial 
functions in diabetic and hypertensive rats. The findings were also supported by 
Kuhad and Copra (2009) whereby tocotrienols and not tocopherols were shown to be 
more effective in preventing biochemical and molecular changes associated with 
diabetes in diabetic rats. Furthermore, hyperlipidaemic diabetic patients provided 
with dietary tocotrienols showed a reduction of L DL-C (Baliarsingh et al., 2005).  
 
1.3.4 CURRENT DOSAGE FORM IN THE MARKET 
Numerous tocotrienol preparations are available in the current market. Most of these 
are in oily liquid form, encapsulated by a softgel capsule shell. This type of 
formulation is popular since the tocotrienols raw materials are readily available in 
oily solution form. 
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1.4 DOSAGE FORMS 
1.4.1 INTRODUCTION 
Dosage forms can be defined as vehicles where the drugs are delivered specifically to 
the intended site of action in the body (Lachman et al., 1986) and some of these 
examples are listed out by Rouge et al. (1996). Various methods were employed to 
deliver these drugs to the specific site. Examples are floating (Whitehead et al., 
1998), mucoadhesive (Cilurzo et al., 2010) and expendable gastroretentive (Klausner 
et al., 2003) dosage forms. Then, there are different types of dosage forms, 
formulated accordingly to their intended route of administration, for example, oral, 
topical, rectal, parenteral, vaginal, inhaled, ophtalmic and otic. They can also be 
categorized according to their respective physical forms, solid, semi-solid or liquid. 
While solid dosage medications include tablets, soft and hard gels, semi-solid 
preparations consist of topical preparations such as gels, ointments and cream based 
products. Liquid dosage forms are syrups and suspensions. Each of these dosage 
forms has its own advantages as well as disadvantages (Lachman et al., 1986). 
 
1.4.2 ADVANTAGES OF SOLID DOSAGE FORMS 
One of the more important advantages offered by solid dosage forms is safety and 
convenience towards the end users. This formulation benefits consumers with basic 
medical knowledge as it provides an accurate form of dosing. For example, it is more 
accurate to swallow a 500 mg dose tablet as compared to taking a liquid medication 
of which dosage is measured using spoons of different sizes.   
 
Solid dosage forms are popular because of their excellent physical property and shelf 
life. Unlike liquids or syrups, formulations of solid drugs rarely contain preservatives 
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like parabens as microorganisms do not trive easily on solid matrix of tablets. From a 
manufacturer’s point of view, it is more convenient to produce solid dosages as they 
are less bulky and less messy as liquids are not involved. The need for continuous 
stirring facilities is not required because these solids do not encounter separation 
problems, hence, lowering the overall manufacturing costs (Lachman et al., 1986; 
Stoltenberg et al., 2011).  
 
1.5 TOCOMAX
®
 20% POWDER 
Tocomax
®
 20% powder is a spray-dried powder, manufactured by Carotech
®
 Bhd, 
Malaysia. It is named as such as it contains 20% (w/w) of mixed tocotrienols and 
alpha tocopherol, mainly extracted from the palm oil fruits, Elaeis guineensis. The 
remaining contents of the Tocomax
®
 20% powder include plant squalenes, 
phytosterols, Co-enzyme Q10 and mixed carotenoids. The product can be best 
described as an orange-coloured powder with a fine texture. Like most tocotrienols 
products, the powder is heat and light sensitive. Being extremely hygroscopic, the 
powder tends to absorb moisture from the environment and clump together, with the 
tendency to form a sticky and non free-flowing mass. Nevertheless, some of the 
advertised applications of Tocomax
®
 20% powder, include dietary nutritional 
supplements, functional ingredients or as vitamin premixes. This is true despite the 
fact that there is still a lack of information with no scientific journals being published 
regarding the bioavailability and tabletting capabilities of the Tocomax
®
 20% 
powder. 
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1.6 SUMMARY AND SCOPE OF STUDY 
Although a number of spray-dried powder containing tocotrienols has emerged in the 
commercial market, most of these products have yet to be assessed for bioavailability. 
Subsequent issues on the tabletting and compressibility properties of these 
tocotrienols containing products were questionable as oil may leach out upon 
compression, giving the tablets an oily and unsightly mottled appearance (Takashima 
et al., 1999). Moreover, the tablets produced should be subjected to stringent in vitro 
and in vivo tests to provide more complete data regarding disintegration time, 
hardness, friability and stability.  
The objectives of this project comprise the following: 
(a) To determine the bioavailability of Tocomax® 20% powder using rats 
(b) To formulate tablets using Tocomax® 20% powder as the active 
ingredient 
(c) To validate a suitable assay for the formulation and to determine its 
stability in various storage conditions 
(d) To determine the bioavailability of the said formulation using human 
subjects 
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CHAPTER 2: IN VIVO EVALUATION OF TOCOMAX
®
 20% POWDER VERSUS 
TWO DIFFERENT TOCOTRIENOL PREPARATIONS IN RATS 
2.1 INTRODUCTION 
The development of Tocomax
®
 20% powder (as described in Section 1.5) illustrates 
the application of the spray-drying technique for converting an oily drug into a solid. 
This technique has often been challenged with issues such as: (1) complexity of the 
process, (2) the expense of more resources such as time, effort and materials to fine 
tune the process and (3) producing a workable end product. Spray drying often 
generates unsuccessful results due to incorrect parameters, inadequate drying time 
which result in a sticky and moist mass and low yield due to thermal degradation of 
drug (Anwar et al., 2011; Freitas and Muller, 1997; Gharsallaoui, 2007). Thus, the 
successful commercialization of Tocomax
®
 20% powder in the local market has also 
proven that spray-drying an oily drug such as tocotrienols into a powder preparation 
is possible.  
 
Despite the success of preparing the tocotrienols into a powder form, there is little 
documentation on the bioavailability of Tocomax
®
 20% powder. Therefore, the aim 
of this part of study was to investigate the systemic uptake of tocotrienols in the form 
of Tocomax
®
 20% powder in comparison with a normal oily preparation (Tocomin
®
 
50%) and also a commercial self-emulsifying system of the tocotrienols with 
enhanced oral bioavailability (Tocovid
®
 Suprabio). The study was carried out using 
Sprague-Dawley rats according to a 3-period, 3-sequence crossover study design.  
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2.2 MATERIALS 
Tocomax
®
 20% powder was obtained from Carotech Bhd, Malaysia. Tocovid
®
 
Suprabio and Tocomin
®
 50% were both obtained from Hovid Bhd, Malaysia and the 
content of each type of tocotrienol isomer in the preparations are listed in Table 2.1. 
 
Table 2.1 Contents of each type of tocotrienol isomers in Tocomax
®
 20% powder (% 
w/w), Tocovid
®
 Suprabio (% w/v) and Tocomin
®
 50% (% w/v) 
 
Tocotrienols preparations 
Percentage of tocotrienol isomers (%) 
alpha gamma delta 
Tocomax
®
 20% powder (% w/w) 4.8 8.2 2.2 
Tocovid
®
 Suprabio (% w/v) 2.6 4.7 1.1 
Tocomin
®
 50% oily formulation (% 
w/v) 
12.3 20.6 5.3 
 
Meanwhile, soya bean oil was also obtained from Hovid Bhd, Malaysia. All the other 
solvents used were either of analytical or HPLC grades and were purchased from 
Merck KGaA (Darmstadt, Germany). 
 
2.3 METHODS 
2.3.1 PREPARATION OF VARIOUS TOCOTRIENOL PREPARATIONS FOR 
ADMINISTRATION TO THE RATS 
A total of 5 mg of mixed tocotrienols (alpha, gamma and delta) of each preparation 
was fed to each rat. The actual amount of each isomer for each preparation is shown 
in the table below (Table 2.2). Meanwhile, the method to prepare each type of 
tocotrienols preparations is stated in the following sections (2.3.1(a), 2.3.1(b) and 
2.3.1(c)). 
 
18 
 
Table 2.2 The actual amount of tocotrienol isomer in each preparation 
Tocotrienols preparations 
Amount of tocotrienol isomers (mg) 
alpha gamma delta 
Tocomax
®
 20% powder (w/w) 1.6 2.7 0.7 
Tocovid
®
 Suprabio (w/v) 1.5 2.8 0.7 
Tocomin
®
 50% oily formulation (w/v) 1.6 2.7 0.7 
 
The values in Table 2.2 were obtained by multiplying the percentage of the 
respective isomers from Table 2.1 with the total amount of tocotrienols preparation 
stated in Section 2.3.1(a), (b) and (c). 
 
2.3.1(a) Preparation of Tocomax
®
 20% powder 
For each gram of Tocomax
®
 20% powder, there were 152.0 mg of mixed tocotrienols 
(alpha, gamma and delta tocotrienols). Therefore, to obtain 5.0 mg of mixed 
tocotrienols, 32.9 mg of Tocomax
®
 20% powder was weighed carefully into a 1 ml 
syringe. This preparation contained 1.6 mg of alpha tocotrienol, 2.7 mg of gamma 
tocotrienol and 0.7 mg of delta tocotrienol.  
 
2.3.1(b) Preparation of Tocovid
®
 Suprabio 
Tocovid
®
 Suprabio were in capsules form and to obtain its contents, the capsules 
were cut open carefully using a penknife. The contents were collected immediately 
into an amber cream jar and stirred for 15 minutes until a homogeneous mixture was 
obtained using a hot plate stirrer (502-P, PMC Industries, Inc, San Diego, USA). 
According to the product label, 600.0 mg (per capsule) of the Tocovid
®
 Suprabio 
contains 50.0 mg of mixed tocotrienols. Therefore, in order to obtain 5.0 mg of 
mixed tocotrienols, 60.0 mg of the mixture was weighed carefully into a 1 ml syringe. 
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This 60.0 mg of Tocovid
®
 Suprabio mixture contained 1.5 mg of alpha tocotrienol, 
2.8 mg of gamma tocotrienol and 0.7 mg of delta tocotrienol. 
 
2.3.1(c) Preparation of Tocomin
®
 50% oily formulation 
According to the product label, 100.0 mg of Tocomin
®
 50% contains 38.2 mg of 
mixed tocotrienols Therefore, to obtain 5.0 mg of mixed tocotrienols, 13.1 mg of the 
Tocomin
®
 50% was required. However, this amount was considered too little to be 
weighed out and may give rise to weighing errors instead. Thus, 1310.0 mg (100 
times higher than the amount required) of Tocomin
®
 50% was weighed into a beaker. 
2690.0 mg of soya oil was then weighed into the same beaker and the mixture was 
then stirred for 15 minutes until a homogeneous suspension was obtained. The 
amount of soya oil was added as such in order to make up the final volume of 4000.0 
mg. 40.0 mg of the prepared mixture was then weighed carefully into a 1 ml syringe, 
and this contained 1.6 mg of alpha tocotrienol, 2.7 mg of gamma tocotrienol and 0.7 
mg of delta tocotrienol.   
 
2.3.2 IN VIVO ABSORPTION STUDIES 
The in vivo study protocol was reviewed and approved by the Ethics Committee on 
Animal Studies, Universiti Sains Malaysia. The study was conducted using 6 adult 
male Sprague Dawley rats, weighing 269.0 to 320 g, (mean = 313.0 g,  S.D. = 15.0 
g), according to a 3-period, 3-sequence crossover study design with a one week 
washout period between the phases. The rats were randomly divided into 3 groups of 
2 rats each and were administered the tocotrienols preparations according to the 
sequence shown in Table 2.3. 
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Table 2.3 Sequence of administration of Tocomax
®
 20% powder, Tocovid
®
 Suprabio 
and Tocomin
®
 50% oily formulation 
 
Group Sequence of administration 
(2 rats/ group) Phase 1 Phase 2 Phase 3 
1 
Tocomax
®
 20% 
powder 
Tocovid
®
 Suprabio 
Tocomin
®
 50% oily 
formulation 
2 Tocovid
®
 Suprabio 
Tocomin
®
 50% oily 
formulation 
Tocomax
®
 20% 
powder 
3 
Tocomin
®
 50% oily 
formulation 
Tocomax
®
 20% 
powder 
Tocovid
®
 Suprabio 
 
 
The rats were fasted for 12 hours prior to administration of the respective 
preparations via oral intubation. Food was also withheld the first 4 hours after dosing 
but the rats had free access to water throughout the study period. For all formulations, 
the dose of mixed tocotrienols administered was 5 mg per rat. Blood samples of 
approximately 0.3 ml were collected from the tail vein into heparinised 
microcentrifuged tubes at 0 (prior to dosing), 1, 2, 3, 4, 6, 8 and 12 hours post 
administration. The blood samples were then centrifuged for 20 minutes at 12800 g. 
Subsequently, 0.2 ml aliquot of plasma from each blood sample was then transferred 
into new microcentrifuge tube. All plasma samples were kept at -20
0
C until analysis.  
 
2.3.3 ANALYSIS OF ALPHA, GAMMA AND DELTA TOCOTRIENOLS 
2.3.3(a) Instrumentation 
Plasma levels of alpha, gamma and delta tocotrienols were determined using a high 
performance liquid chromatographic (HPLC) method developed and validated by 
Yap et al. (1999). The HPLC system comprised of a Waters 600E Multisolvent 
Delivery System (Maple Street Milford, USA), Waters 2475 Multi λ Fluorescence 
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Detector (Maple Street Milford, USA), a Waters 717 Plus Autosampler (Maple Street 
Milford, USA), fitted with a 50 μl sample loop (Rheodyne, California) and a data 
acquisition and analysis software, Waters Empower
TM
 2 Data Software (Maple Street 
Milford, USA). A Genesis C18 (250 x 4.6 mm id, 4μ) (Grace Davison Discovery 
Sciences, Illinois, USA) analytical column, fitted with a refillable guard column 
(2mm x 2cm) (Upchurch Scientific, Oak Harbour, WA, USA), packed with Perisorb 
RP-18 (30 – 40 μm, pellicular, Upchurch Scientific, Oak Harbour, WA, USA), was 
used for the chromatographic separation. The mobile phase used was pure methanol. 
The system was operated at ambient room temperature (25
0
C) with the detector 
operating at an excitation wavelength of 296 nm and emission wavelength of 330 nm 
while the sensitivity was set at 2000 EUFS. Analyses were run at a flow rate of 1.5 
ml/minute and the samples were quantified using peak area.   
 
2.3.3(b) Sample preparation 
Prior to analysis, a 100 μl aliquot of sample was accurately measured into a 
microcentrifuge tube (Eppendorf, Hamburg, Germany) and was deproteinized by 
adding in 200 μl of acetonitrile: tetrahydrofuran (3:2, v/v). The mixture was then 
vortex-mixed for 2.5 minutes using a vortex mixer (Barnstead Thermolyne MaxiMix 
Vortex Mixer, USA) and then centrifuged (MiniSpin Plus, Eppendorf, Germany) at 
12800 g for 20 minutes. Approximately 100 μl of the resulting supernatant was 
injected into the HPLC system.  
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2.3.4 DATA AND PHARMACOKINETIC ANALYSIS 
Corrections were made for all measured values due to the presence of endogeneous 
peaks in the blank plasma itself. This was carried out by subtracting the tocotrienols 
concentration determined at 0 hour (prior dosing) from all the measured values 
obtained. The oral bioavailability of tocotrienols from three different preparations 
were compared using the pharmacokinetic parameters, area under the plasma 
concentration-time curve from time zero to the last sampling time, 12 hours after 
dosing (AUC0-12h), peak plasma concentration (Cmax) and time to reach peak plasma 
concentration (Tmax). While Cmax and Tmax values were obtained directly from the 
plasma concentration values (Weiner, 1981), the AUC0-12h values were calculated 
using the trapezoidal formula. The other common parameter used for bioavailability 
studies, area under plasma concentration-time curve from time zero to infinity 
(AUC0-∞), was not taken into consideration as it would require the calculation of area 
under the plasma concentration-time curve from time t to infinity (AUCt-∞), which in 
turn, utilizes the relationship Ctt/ke, whereby, Ctt is the plasma concentration at the 
last sampling point and ke, the elimination rate constant. Since the amount of plasma 
samples that could be taken from the rats were rather limited (as compared to human 
subjects), the estimation of ke values from the terminal slope of the plasma 
concentration-time curve is more difficult and may give rise to errors. This is 
especially true when plasma concentrations are low, where the last few 
concentrations were near the quantification limit of the assay method or below the 
detection limit. Also, it should be noted that for all 3 preparations, the Ctt values were 
very low and almost baseline values. Hence, AUCt-12h is deemed sufficient for 
comparing the bioavailability of the 3 preparations. 
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2.3.5 STATISTICAL ANALYSIS 
The AUC0-12h and Cmax values obtained were analyzed statistically using an analysis 
of variance (ANOVA) procedure appropriate for a three-way crossover study design 
that distinguishes effects due to group, subjects/groups, period and treatment 
(Wagner, 1975). These values were logarithmic transformed prior to statistical 
analysis. Pairwise comparisons of the three formulations were carried out using the 
Tukey’s test when a statistically significant difference (p < 0.05) was detected using 
the ANOVA procedure. On the other hand, Tmax values of the three preparations 
were also analyzed using the Friedman’s Test. A statistically significant difference 
was considered at p < 0.05. 
 
The 90% confidence intervals for the ratio of AUC0-12h and Cmax values for all three 
test formulations were calculated using the two one-sided test procedures 
(Schuirmann, 1987).    
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2.4 RESULTS 
The mean plasma alpha, gamma and delta tocotrienols concentrations versus time 
profiles obtained of the three different tocotrienols preparations are shown in Figures 
2.1(a), 2.1(b) and 2.1(c) respectively. Since the doses of all 3 tocotrienol isoforms in 
all the 3 preparations were essentially similar (albeit a slight difference between the 
Tocomax
®
 20% powder and Tocovid
®
 Suprabio in alpha and gamma tocotrienols), 
no adjustment or normalization of the doses was carried out. From the plots obtained, 
it can be seen that the Tocomax
®
 20% powder had the highest plasma levels for 
gamma and delta tocotrienols but showed comparable plasma profiles for the alpha 
tocotrienol isomer as compared to Tocovid
®
 Suprabio. Meanwhile, Tocomin
®
 50% 
oily formulation showed the lowest plasma levels for all three different isomers of 
tocotrienols.  
 
Tables 2.4(a), 2.4(b) and 2.4(c) show the individual numerical values of AUC0-12h, 
Cmax and Tmax estimated from the plasma alpha, gamma and delta tocotrienols 
concentration versus time profiles of the three preparations respectively. There was a 
statistical significant difference among the logarithmic transformed AUC0-12h values 
(p < 0.05) of the three preparations for all three tocotrienol isomers. Further 
calculations using the Tukey’s test showed that the significant difference lies 
between the AUC0-12h values of tocotrienols administered as Tocomax
®
 20% powder 
and Tocomin
®
 50% oily formulation as well as that between Tocovid
®
 Suprabio and 
Tocomin
®
 50% oily formulation for all three alpha, gamma and delta tocotrienols. 
However, the Tukey’s test also revealed that there were no significant differences for 
AUC0-12h values calculated between Tocomax
®
 20% powder and Tocovid
®
 Suprabio.
